As part of our ongoing series here at The Acquirer’s Multiple, we provide this feature article titled ‘Stock in Focus‘ where we focus on one of the stocks from our Stock Screeners.
One of the cheapest stocks in our Stock Screeners is:
Innoviva Inc (NASDAQ: INVA)
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance’s respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
A quick look at the share price history for the company (below) over the past twelve months shows that the price is up 51%. Here’s why the company remains undervalued.
Summary
Market Cap: $1.34 Billion
Enterprise Value: $1.65 Billion
Operating Earnings
Operating Earnings: $375 Million
Acquirer’s Multiple
Acquirer’s Multiple: 4.4
Free Cash Flow (TTM)
Free Cash Flow: $363 Million
FCF/EV Yield
FCF/EV Yield: 22%
Other Indicators
Piotroski F-Score: 5
Altman Z-Score: 3.73
Beneish M-Score: -3.29
Shareholder Yield
Shareholder Yield: 29.31%
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:
2 Comments on “Stock In Focus – TAM Stock Screener – Innoviva Inc (NASDAQ: INVA)”
Is “Theravance” a copy-paste typo? If so, is the rest of the statement referring to Theravance or to Innoviva?
Innoviva, was formerly known as Theravance, Inc in 2016.